Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 17 von 80

Details

Autor(en) / Beteiligte
Titel
Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer
Ist Teil von
  • Zhōnghuá zhŏngliú zázhì, 2008-12, Vol.30 (12), p.944
Ort / Verlag
China
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
  • To evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer. Thirty-two patients with anthracycline-resistant metastatic breast cancer were treated with a docetaxel and capecitabine combination regimen. All patients received oral administration of capecitabine at a dose of 1250 mg/m(2) twice daily, within 30 min after meal on D1 to D14, and intravenous infusion of docetaxel at a dose of 75 mg/m(2) on D1. The regimen was repeated every 3 weeks. A total of 126 cycles of DC regimen were administered in the 32 cases, with a median of 4 cycles. The overall response rate was 46.9%. Among the 32 patients, there were complete response in 1, partial response in 14, stable disease in 11 and progressive disease in 6 cases. The median time to progression (TTP) was 5.6 months. The one-year survival rate was 56.3%. The effective cases in different metastatic organs were: 8 cases in the lung, 6 cases in the liver,

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX